Table 2.
Demographics of individuals used for protein analysis.
| Case Number | Diagnosis | Age | Sex | PM (h) | APOE | Braak | BT | MMSE |
|---|---|---|---|---|---|---|---|---|
| 1 × 5070 | Control | 97 | F | 12 | 3/3 | 1 | 2 | 26 |
| 2 × 5302 | Control | 83 | F | 72 | 2/4 | 1 | 29 | |
| 3 × 5512 | Control | 89 | F | 12 | 2/3 | 2 | 30 | |
| 4 × 5049 | Control | 102 | F | 9 | 3/3 | 1 | 27 | |
| 5 × 4870 | Control | 63 | F | 8 | 3/3 | 1 | 0 | 30 |
| 6 × 4689 | Control | 79 | F | 6 | 3/3 | 0 | 1 | 27 |
| 7 × 5248 | Control | 93 | F | 18 | 3/3 | 1 | 30 | |
| 8 × 5447 | Control | 91 | F | 8 | 3/3 | 1 | 28 | |
| 9 × 5759 | AD | 87 | F | 18 | 3/3 | 6 | 9 | 18 |
| 10 × 5798 | AD | 87 | F | 7 | 3/3 | 5 | 3 | 11 |
| 11 × 5799 | AD | 82 | F | 15 | 6 | 26 | 9 | |
| 12 × 5764 | AD | 82 | F | 8 | 3/4 | 6 | 33 | 23 |
| 13 × 5763 | AD | 94 | F | 24 | 3/4 | 5 | 25 | 13 |
| 14 × 5792 | AD | 93 | F | 10 | 3/3 | 5 | 8 | 22 |
| 15 × 5761 | AD | 89 | F | 3/4 | 5 | 3 | 25 | |
| 16 × 5755 | AD | 83 | F | 12 | 4/4 | 6 | 18 | 19 |
PM: time of tissue harvesting post-mortem.
APOE: genotyping results for ApoE2 (2), ApoE3 (3) and ApoE4 (4).
BT: Blessed test results for cognitive impairment [72] with scores ranging from 0 (no impairment) to 33 (severe impairment). Scores were not available for 5 control subjects.
Braak staging marks the disease propagation with respect to the location of the tangle-bearing neurons and the severity of changes with 1–2: clinically silent cases; 3–4: incipient Alzheimer's disease; 5–6: fully developed Alzheimer's disease [73].
MMSE: Mini-Mental State Examination, a score of 20–24 suggests mild dementia, 13–20 suggests moderate and <12 implies severe dementia.